Key Points
Question: Are specific molecular features associated with benefit from the addition of apalutamide to androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer?
Key Points
Question: Are specific molecular features associated with benefit from the addition of apalutamide to androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer?